Bio News

Ionkura reported a median overall survival of 20.8 months among patients with metastatic uveal melanoma in a Phase 1 trial of roginolisib.
Roginolisib is a PI3K delta inhibitor that reverses immunosuppression to prevent cancer cell growth.
Based on these results, Ionkura is pursuing expansion into solid tumor indications.

Biobook Team
biobookmedia@biobook.co.krEuropean CHMP Recommends Approval of AstraZeneca’s Blood Pressure Drug Baxpendi
Novo Seeks U.S. and European Approval for Sickle Cell Drug Etavopivat
Rezolute Meets Primary Endpoint in Phase 3 Trial for Tumor Hyperinsulinism; FDA Meeting Ahead
Five Brain Disease Startups Raise $450 Million in a Few Weeks
American Cancer Society Revises Prostate Cancer Screening Guidelines for First Time in 16 Years
Shin Dong-kook Raises Stake in Hanmi Science to 30.18% With Over-the-Counter Purchase of 1.38 Million Shares